Journal: Cell Death & Disease

Article Title: Oncogenic and microenvironmental signals drive cell type specific apoptosis resistance in juvenile myelomonocytic leukemia

doi: 10.1038/s41419-025-07479-2

Figure Lengend Snippet: CD11b + myeloid cells were treated with BH-3 mimetics, A1155463 (10 μM), S63845 (1 μM), ABT737 (3 μM), ABT199 (5 μM) for 48 h. Then, cells were stained for the surface markers CD11b + , Ly6G + , and Ly6C + followed by staining for AV and 7AAD, and the viable cells were determined as AV - 7AAD - on flow cytometry. The percentage of specific apoptosis induced by BH3 mimetics was calculated for the specific cell types: A CD11b + - myeloid cells, B CD11b + Ly6C + - monocytes and C CD11b + Ly6G + - neutrophils. Freshly isolated LSK stem and progenitor cells (cultured with or without cytokines) were treated with the BCL-X L (A1155463) or MCL-1 (S63845) inhibitor for 48 h. The percentage of specific apoptosis was calculated for LSK cells: D in the presence (of TPO, FLT3, and SCF) and E in the absence of cytokines. The gating strategy was performed as described in Supplementary Fig. . All data are presented as Mean ±SEM ( n = 1–3; ≥3 independent experiments).

Article Snippet: Apoptosis of LSK and CD11b + cells was assessed after treatment with BH3-mimetics: ABT737 (Selleck Chemicals), ABT199 (Selleck Chemicals), A115546, S63845 (Synthesis) and Runx inhibitor (Tocris).

Techniques: Staining, Flow Cytometry, Isolation, Cell Culture

Journal: iScience

Article Title: Tracing specificity of immune landscape remodeling associated with distinct anticancer treatments

doi: 10.1016/j.isci.2025.112071

Figure Lengend Snippet:

Article Snippet: Another cohort was treated for 10 or 20 days, every day by intraperitoneal injection with Trametinib (1 mg/kg, MEK inhibitor; TargetMol) plus ABT-737 (30 mg/kg, BCL-XL inhibitor; TargetMol), both diluted in Cremophore and NaCl 0.9%.

Techniques: Recombinant, Software